Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight over 68 weeks, compared with 3.1% with placebo
Many people report feeling more energized within just a few days of their injection, helping them power through workouts and stay active all day long
Surgery success rates are generally good for pain relief (70 to 90% improvement in leg pain symptoms), but come with risks: infection, nerve damage, disc reherniation (5 to 15% recurrence rate after microdiscectomy), and adjacent segment disease with fusion (20 to 30% develop problems within 10 years)
This peptide blend is intended for use only under qualified medical supervision
Not approved for human consumption, medical, veterinary, or household use.